GRIFOLS | GRF - Selling And Administration Expenses


GRIFOLS reported EUR281M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alcon AG USD 882M 19M Mar/2026
Amadeus IT EUR 497.5M 206.6M Mar/2025
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 355M 74.62M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
Cie Automotive EUR 315.66M 28.06M Dec/2024
Demant DKK 6.09B 135M Dec/2025
Ence Energia y Celulosa EUR 29.1M 2M Sep/2024
Essilor EUR 5.62B 4.53B Dec/2025
Ferrovial EUR 906M 52M Dec/2024
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
GRIFOLS EUR 281M 5.7M Mar/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Inditex EUR 2.51B 7.98B Jan/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Philips EUR 1.18B 121M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.33B 419M Mar/2026
Smith & Nephew USD 1.42B 65M Dec/2025
UCB EUR 1.47B 193M Dec/2025
Viscofan EUR 72.59M 4.52M Mar/2025